Abstract: The present invention relates to therapeutic combinations comprising WNT inhibitors and methods for treating cancers using combination therapy.

Abstract: Disclosed are a low-shrinkage, high-strength, and large ceramic plate and a manufacturing method thereof. The method comprises the following steps: (1) preparing a ceramic raw material powder; (2) subjecting an acicular wollastonite to surface coating with a silane coupling agent and to pre-dispersion with a fumed silica to obtain a pre-treated acicular wollastonite; and (3) thoroughly mixing the ceramic raw material powder and the pre-treated acicular wollastonite and granulating the resulting mixture, the amount of the pre-treated acicular wollastonite added being 10 wt % to 30 wt % of the ceramic raw material powder, and subjecting the resulting granules to dry pressing and sintering to obtain the large ceramic plate. The acicular wollastonite is incorporated into the manufacturing of the large ceramic plate to take full advantage of the reinforcing effect and low sintering shrinkage characteristics of the acicular wollastonite. The invention reduces sintering shrinkage and increases product strength.

Abstract: The present invention relates to therapeutic combinations comprising WNT inhibitors and methods for treating cancers using combination therapy.

Abstract: Disclosed herein are biomarkers related to WNT signal transduction pathway, as well as methods and kits comprising the same. Further, the present disclosure relates to the use of the biomarkers in patient selection, companion diagnostics, and treatment of cancer.

Abstract: Disclosed are a low-shrinkage, high-strength, and large ceramic plate and a manufacturing method thereof. The method comprises the following steps: (1) preparing a ceramic raw material powder; (2) subjecting an acicular wollastonite to surface coating with a silane coupling agent and to pre-dispersion with a fumed silica to obtain a pre-treated acicular wollastonite; and (3) thoroughly mixing the ceramic raw material powder and the pre-treated acicular wollastonite and granulating the resulting mixture, the amount of the pre-treated acicular wollastonite added being 10 wt % to 30 wt % of the ceramic raw material powder, and subjecting the resulting granules to dry pressing and sintering to obtain the large ceramic plate. The acicular wollastonite is incorporated into the manufacturing of the large ceramic plate to take full advantage of the reinforcing effect and low sintering shrinkage characteristics of the acicular wollastonite. The invention reduces sintering shrinkage and increases product strength.

Abstract: A honeycomb rib structure in a rotating gantry of a proton includes an upper honeycombed rib plate and a lower honeycombed rib plate which are mounted in a cylindrical body through a plurality of connecting structures. The upper and lower honeycombed rib plates are symmetrically arranged, and are spliced by a plurality of basic structures which are in a regular hexagonal shape. Connecting nodes between the adjacent basic structures are of a ring structure. Densities of the upper and lower honeycombed rib plates are adjusted through a density increasing structure.

Abstract: The present invention relates to compounds as inhibitor of WNT signal transduction pathway, as well as a composition comprising the same. Further, the present invention relates to the use of the compounds in the treatment of cancer.

Abstract: The present invention relates to compounds as inhibitor of WNT signal transduction pathway, as well as a composition comprising the same. Further, the present invention relates to the use of the compounds in the treatment of fibrosis.

Abstract: The present invention relates to compounds as inhibitor of WNT signal transduction pathway, as well as a composition comprising the same. Further, the present invention relates to the use of the compounds in the treatment of cancer.

Abstract: The present invention relates to compounds as inhibitor of WNT signal transduction pathway, as well as a composition comprising the same. Further, the present invention relates to the use of the compounds in the treatment of fibrosis.

Abstract: Embodiments of chemically defined cell culture media containing nutrients and growth factors free of any serum for culturing cells such as mesenchymal stem cells and methods of using embodiments of the cell culture medium for expanding cell populations such as mesenchymal stem cells while maintaining a pluripotent phenotype and methods of inducing chondrogenesis and osteogenesis of mesenchymal stem cells by admixing differentiation factors into embodiments of the cell culture medium.

Abstract: A honeycomb rib structure in a rotating gantry of a proton includes a plurality of upper honeycomb ribs and a plurality of lower honeycomb ribs which are mounted in a cylindrical body through a plurality of connecting structures. The plurality of upper honeycomb ribs and the plurality of lower honeycomb ribs are symmetrically arranged, and are spliced by a plurality of basic structures in a regular hexagonal distribution. Connecting nodes between the adjacent basic structures are of a ring structure. Densities of the plurality of upper honeycomb ribs and the plurality of lower honeycomb ribs are adjusted through a density adjustment structure.

Abstract: The present invention relates to compounds as inhibitor of WNT signal transduction pathway, as well as a composition comprising the same. Further, the present invention relates to the use of the compounds in the treatment of cancer.

Abstract: The present invention related to a compound having the structure of Formula I as inhibitor of WNT signal transduction pathways, as well as a composition comprising the compound. Further, the present invention relates to the use of the compound and the method of inhibiting the WNT signal transduction pathways.

Abstract: The present invention relates to therapeutic combinations comprising WNT inhibitors and methods for treating cancers using combination therapy.

Abstract: Disclosed herein are biomarkers related to WNT signal transduction pathway, as well as methods and kits comprising the same. Further, the present disclosure relates to the use of the biomarkers in patient selection, companion diagnostics, and treatment of cancer.

Abstract: The present invention relates to compounds as inhibitor of WNT signal transduction pathway, as well as a composition comprising the same. Further, the present invention relates to the use of the compounds in the treatment of fibrosis.

Abstract: The present invention relates to compounds as inhibitor of WNT signal transduction pathway, as well as a composition comprising the same. Further, the present invention relates to the use of the compounds in the treatment of cancer.

Abstract: The present invention relates to compounds as inhibitor of WNT signal transduction pathway, as well as a composition comprising the same. Further, the present invention relates to the use of the compounds in the treatment of fibrosis. Fibrosis is the formation of excess fibrous connective tissue in an organ or tissue in a reparative or reactive process. Fibrosis is the end result of chronic inflammatory reactions induced by a variety of stimuli including persistent infections, autoimmune reactions, allergic responses, chemical insults, radiation, and tissue injury.

Abstract: The present invention relates to compounds as inhibitor of WNT signal transduction pathway, as well as a composition comprising the same. Further, the present invention relates to the use of the compounds in the treatment of cancer.